Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a research-based biopharmaceutical enterprise in China involved in the discovery, manufacturing, and marketing of innovative and generic medicines. The company focuses on oncology, anesthesia, contrast agents, cardiovascular, and metabolic disease treatments, developing small-molecule formulations and biologics. Principal revenue drivers stem from commercial domestic sales of innovative proprietary prescription oncology therapies, generic formulations, and active pharmaceutical ingredients. Jiangsu Hengrui serves public and private hospital systems, medical research clinics, and healthcare distribution networks across mainland China and overseas markets. The enterprise occupies a leading market position as one of China's largest pharmaceutical companies by market value and research and development expenditure. Jiangsu Hengrui Pharmaceuticals Co., Ltd. is headquartered in Lianyungang, China, and its common shares are listed on the Shanghai Stock Exchange.
15 of the funds FundTelligence covers report a position in Jiangsu Hengrui Pharmaceuticals.
- Legal name
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Sector
- Health Care
- Country
- China
- Funds holding it
- 15
- Exposure themes
- Multiple, Treatment, Women's Health
Funds holding Jiangsu Hengrui Pharmaceuticals
- DNB Fund Women's Health — DNB · 1.29 % (full portfolio disclosed, August 2026)
- DWS Invest Chinese Equities — DWS · 1.14 % (full portfolio disclosed, June 2026)
- Templeton Asian Growth Fund — Franklin Templeton · 0.91 % (full portfolio disclosed, September 2026)
- JPM China Fund — JPM · 0.57 % (full portfolio disclosed, June 2026)
- Schroder ISF Asian Opportunities — Schroders · 0.4 % (full portfolio disclosed, June 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.39 % (full portfolio disclosed, October 2026)
- Handelsbanken Asia Tema — Handelsbanken · 0.16 % (full portfolio disclosed, August 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 15 funds holding it.